Overview

• At the request of defense counsel for owner Ariel García Furfaro, the Malbrán institute said contamination could have occurred at several critical stages before or after release, especially during aseptic handling, and warned such failures would violate good manufacturing practices.
• HLB Pharma technical director José Antonio Maiorano returned to expand his testimony before Judge Ernesto Kreplak and prosecutor Laura Roteta after initially declining to testify.
• Two defendants testified that microbiology chief Adriana Iudica detected a positive contamination result in at least lot 31202 and neither repeated the test nor blocked distribution after quarantine.
• In a written response, Iudica called the result a false positive, said she requested a contramuestra that never arrived, denied signing final approval, and pointed to possible procedural errors by a novice analyst.
• The court is set to define the procedural situation of 17 accused as the García brothers and other executives remain detained, with investigators linking roughly 96 deaths to contaminated lots 31202 and 31244.